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Abstract
Multiple physiological and psychological regulatory domains may contribute to the
pathophysiology of pain in temporomandibular disorder (TMD) and other bodily pain conditions.
The purpose of this study was to evaluate the relationship between multisystem dysregulation and
the presence of TMD pain, as well as the presence of different numbers of comorbid pain
conditions in TMD. Secondary data analysis was conducted in 131 non-TMD (without comorbid
pain) controls, 14 TMD subjects without comorbid pain, 78 TMD subjects with 1 comorbid pain,
and 67 TMD subjects with multiple comorbid pain conditions who participated in a TMD genetic
study. Twenty markers from sensory, autonomic, inflammatory, and psychological domains were
evaluated. The results revealed that 1) overall dysregulation in multiple system domains (OR
[odds ratio] = 1.6, 95% confidence interval [CI] = 1.4–1.8), particularly in the sensory (OR = 1.9,
95% CI = 1.3–2.9) and the psychological (OR = 2.1, 95% CI = 2.1–2.7) domains, were associated
with increased likelihood of being a painful TMD case; and 2) dysregulations in individual system
domains were selectively associated with the increased odds of being a TMD case with different
levels of comorbid persistent pain conditions. These outcomes indicate that heterogeneous
multisystem dysregulations may exist in painful TMD subgroups, and multidimensional
physiological and psychological assessments can provide important information regarding
pathophysiology, diagnosis, and management of pain in TMD patients.
Perspective—The concurrent assessment of multiple physiological and psychological systems is
critical to our understanding of the pathophysiological processes that contribute to painful TMD
and associated comorbid conditions, which will ultimately guide and inform appropriate treatment
strategies that address the multisystem dysregulation associated with complex and common
persistent pain conditions.
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Painful temporomandibular disorders (TMDs) are a heterogeneous group of conditions that
affect 5% of the adult population.30 In addition to facial pain, concomitant bodily pain
conditions are reported by approximately 60% of individuals with painful TMD.52,53,77
Recent studies suggest different pathophysiologies in TMD subgroups with localized versus
generalized bodily pain profiles.52,68 Generalized bodily pain has also been associated with
the persistence of TMD symptoms55,57,80 and poor treatment outcome.33,58 Therefore, the
relationship between bodily pain profiles and the underlying pathophysiology for TMD pain
warrants further exploration to better inform mechanism-based diagnosis and treatment in
TMD.
Extensive literature suggests that multiple regulatory domains associated with sensory,
autonomic, inflammatory, and psychological function may all contribute to the
pathophysiology of pain in TMD and other bodily pain conditions.13,24,35,54,56,59,66,85,89
These regulatory domains are interconnected and are integrated by the central nervous
system (CNS) to maintain homeostasis.11,14 Pain experience can therefore be modulated
through different pathways within this integrated CNS regulatory network.11 Because of the
interconnectivity between different regulatory domains and the parallel multisystem
modulation within the CNS, multiple compensatory systems contribute to pain processing
and modulation. Therefore, an assessment of the function of multiple regulatory systems
should be assessed when evaluating the diverse heterogeneous processes that contribute to
the experience of chronic pain.
Consistent with the biopsychosocial model for chronic pain,19 multidimensional physical
and psychosocial measures are required to understand the etiologic factors and mechanisms
that underlie chronic TMD.1,18,62 However, current assessment and diagnosis of TMD is
primarily based on signs and symptoms associated with the orofacial region, which fails to
integrate the contributions from other system domains, resulting in an incomplete
understanding of the pathophysiological mechanisms that contribute to painful TMD
conditions.
The aims of this study are to evaluate regulatory systems that are associated with painful
TMD, as well as with TMD subgroups that express different numbers of comorbid bodily
pain conditions. We hypothesize that compared to controls, 1) the sum measure of
multisystem dysregulation is associated with the odds for painful TMD case status, as well
as for TMD subgroup status, which is based on the number of comorbid pain/sensory
conditions; and 2) individual domain measures of dysregulation are associated with the odds
for painful TMD case status, as well as for TMD subgroup status based on the number of
comorbid pain conditions. In this study, clinical pain profiles were also detailed for TMD
subgroups. Part of this work was presented at the 2012 annual scientific meeting of the
American Academy of Orofacial Pain.
Methods
Study Participants and Classification
This study is a secondary analysis using existing data from a case-control study investigating
genetic risk factors for TMD (R01 DE 16558, L.D. and W.M.). Among all 349 participants
in whom comorbid pain and multisystem regulation were measured, 290 subjects fulfilled
the inclusion/exclusion criteria and were included in this study. Data were collected between
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2005 and 2009. Female volunteers were recruited from the Orofacial Pain Clinic at the
University of North Carolina at Chapel Hill, NC, as well as from the university campus and
community by advertisements, flyers, and mass email. Participation was limited to white
women because of the higher prevalence of TMD in women than in men, and to avoid
problems of population stratification in assessing genetic associations. Participants were
aged 18 to 60 years old. Exclusion criteria included the following self-reported medical
conditions: diabetes, kidney disease, heart failure, chronic respiratory disease, epilepsy or
seizure disorder, or high blood pressure not controlled with medication. Women who were
pregnant, nursing, undergoing orthodontic treatment, dialysis, radiation, or chemotherapy
were similarly excluded from participation, as were participants with trauma or surgery on
the head, face, or neck within the past 6 months. This study was approved by the Biomedical
Institutional Review Board of the University of North Carolina at Chapel Hill. Written
informed consent was obtained from all study participants.
TMD Case Classification—Case classification of TMD was based on the following
criteria: 1) a self-reported history of pain in the temporomandibular region for at least 5 days
in the month preceding the clinical examination and 2) the presence of myalgia and/or
arthralgia of TMD based on a modified version of the Research Diagnostic Criteria for
Temporomandibular Disorders (RDC/TMD; see Chen et al12 for detailed descriptions). This
RDC/TMD clinical examination was performed by calibrated examiners on all subjects to
determine TMD case or noncase status.
Classification of Comorbid Pain Conditions—The presence of 7 persistent pain
conditions, namely, fibromyalgia, chronic fatigue syndrome (CFS), irritable bowel
syndrome (IBS), interstitial cystitis, chronic pelvic pain, frequent headaches, and frequent
low back pain, were examined by self-report (see Clinical Pain Measures section). TMD
cases were further arbitrarily classified into 3 subgroups based on the number of comorbid
pain conditions: 1) TMD only (without comorbid pain); 2) TMD + 1 pain (with 1 comorbid
pain condition); and 3) TMD +≥2 pain (with multiple, ie, 2 or more, comorbid pain
conditions).
Control subjects reported no history of orofacial pain within the preceding 6 months and no
prior diagnosis of TMD. In addition, the RDC/TMD clinical examination determined the
absence of arthralgia and myalgia. Controls were also of absence of persistent comorbid
pain conditions.
Clinical Pain Measures
Self-reported questionnaires were used to assess the severity and impact of facial pain and
other bodily pain in TMD and control participants.
Comprehensive Pain Symptom Questionnaire—The Comprehensive Pain Symptom
Questionnaire is a self-report instrument assessing presence of multiple pain symptoms and
their associated characteristics. The presence of the comorbid persistent pain conditions (ie,
fibromyalgia, CFS, IBS, interstitial cystitis, and chronic pelvic pain) were determined by the
following question: “Do you have any of the following conditions or symptoms?” The
presence of frequent headache(s) was determined by headaches that have been present for at
least 3 months or at least 10 episodes in the last year, and on an average of 1 or more
headache day per month. The presence of frequent low back pain was determined by a
positive history and at least 11 episodes of low back pain in the past 12 months. These
frequency criteria were arbitrarily selected to represent persistency of pain based on
available data. Psychometric properties of the instrument have been assessed for items such
as presence of jaw pain (in past 30 days and lifetime), headache in the past year, and jaw
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pain frequency. The validity coefficients range .85 to 1.0 versus expert interview, and
temporal stability ranges .7 to .9 over 3 to 7 days (R. Ohrbach et al, 2011, unpublished data).
Graded Chronic Pain Scale—The Graded Chronic Pain Scale (GCPS) includes 6 items
that rate the intensity of current pain as well as intensity and pain interference with activities
in the past 6 months. All items are rated from 0 to 10. The derived pain severity score is
graded into 4 hierarchical classes: Grade I, low disability–low intensity; Grade II, low
disability–high intensity; Grade III, high disability–moderately limiting; and Grade IV, high
disability–severely limiting. GCPS has been validated in primary care and chronic pain
patients.81 In the present study, Grade I and Grades II to IV were dichotomized to represent
the absence (Grade I) or presence (Grades II–IV) of “clinical significant pain,” as persons
with Grades II to IV commonly present with intense pain and/or pain-related dysfunctions.80
We assessed GCPS rating for both facial pain and “other pain” (ie, bodily pain other than
facial pain).
Screening Pain Self-Report—The Screening Pain Self-Report is a 5-item questionnaire
that rates the recent pain intensity (ie, average, highest, and lowest; range 0–100), average
percentage of waking day during which individuals experience pain, and a rating of current
pain corresponding to descriptive words that represent the sensory (intensity) and affective
(unpleasantness) domains of the pain experience.23
Multisystem Regulation Measures
Based on evidence of system contributions to pain amplification and on availability of data
being collected, we selected 4 domains to investigate the association of impairments in
multiple domains with TMD and TMD with common comorbidities. These domains were
sensory, autonomic, inflammatory, and psychological domains, which are domains that
appear to differ between chronic TMD cases and non-TMD cases.20,25,39,40,68
Sensory Domain Measures—Sensory responses to pressure pain and heat pain stimuli
were selected as they have been associated with TMD cases.25,52 As detailed below,
multiple measures were selected to examine different components of sensory processing and
regulation.25
Pressure Pain Sensitivity: Pressure pain threshold (PPT) at lateral epicondyle and
widespread palpation tenderness (WPT) were assessed to reflect generalized pressure pain
sensitivity.12 The PPT was measured using a flat-tipped algometer (Pain Diagnosis and
Treatment, Great Neck, NY) applied to lateral epicondyle. Pressure was applied at a steady
rate of 1 kg/second until the participant indicated that she felt pain. After an initial test trial,
2 subsequent and consecutive readings that differed by no more than .2 kg were averaged
and recorded as the PPT. Two reproducible readings were generally obtained within 3 trials
after the initial test trial. WPT was determined by digital palpation examination at 18
predefined bodily sites modeled after the American College of Rheumatology’s 1990
criteria86 for fibromyalgia tender points examination: occiput, trapezius, supraspinatus,
lower cervical, second rib, lateral epicondyle, knee, gluteal, and greater trochanter. Three
pounds of digital palpation pressure were applied bilaterally for 2 seconds to each site. At
each location, a response of pain to palpation was recorded as “tenderness.” WPT was
classified as present when palpation tenderness was elicited bilaterally and above and below
the waist, that is, at least in diagonal locations.
Heat Pain Sensitivity: Heat pain tolerance, temporal summation, and a single (first) heat
pain rating were selected for heat pain sensitivity. These measures were assessed using a
commercially available thermal stimulator (Medoc Ltd, Ramat Yishai, Israel). This device
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delivered computer-controlled slowly increasing thermal stimuli to the skin on the left
medial ventral forearm at a rate of .5ºC/second from an adapting temperature of 39ºC. The
subject terminated the stimuli by pressing a button when it became intolerable (thermal pain
tolerance). Thermal pain tolerance was defined as the highest temperature that could be
tolerated (with an upper limit of 50ºC). Four sites were tested for tolerance, with each site
being at least 1.5 inches apart. Four trials of tolerance were conducted to obtain an average
temperature value.
Following heat pain tolerance testing, participants judged the pain intensity evoked by
suprathreshold heat stimuli, verbally reporting on a numerical rating scale (NRS) between 0
and 100, where 0 represented no pain and 100 represented the most intense pain imaginable.
Participants were told that they would receive 10 thermal stimuli in a row and would be
verbally cued to report their peak pain intensity after each stimulus. For more detailed
description of the protocol, see Greenspan et al.25 NRS responses to repeated thermal
stimuli were plotted against time to derive the summary measure of temporal summation for
each subject as the slope of a linear regression line fitted for the first 5 NRS responses. Also,
the subject’s first NRS was used as a measure of initial thermal sensitivity.
Autonomic Domain Measures—Resting blood pressure (BP, systolic [SBP], diastolic
[DBP]) and heart rate (HR) were selected because of data availability and because elevations
in these measures have been observed in TMD and associated pain conditions and have been
related with central pain dysregulation.4–6,34,40,61,89 BP and HR were measured in a seated
position after a rest period of 3 to 5 minutes, using an autonomic monitor (Dinamap; GE
Healthcare, Milwaukee, WI). A pneumatic cuff was positioned around the right arm. Three
readings were taken 2 minutes apart and were averaged for BP and HR measures. Rate
pressure product (RPP = HR × SBP) was also evaluated to reflect the autonomic nervous
system function. The hemodynamic components of RPP are modulated by both sympathetic
and parasympathetic branches of the autonomic nervous system. RPP has been used in
cardiology as an indicator of cardiac workload9 and myocardial oxygen consumption.21
Inflammatory Domain Measures—Circulating cytokines were selected because of their
association with increased pain in TMD and related pain conditions.3,27,28,78,83 Cytokines
are small intracellular regulatory proteins secreted by immune cells that contribute to the
pathophysiology of TMD and related comorbid conditions. Elevated levels of
proinflammatory cytokines (eg, interleukin-1 [IL-1] and interleukin-8 [IL-8]) have been
found locally in temporomandibular joint fluid29,42,48,74 and systemically in circulating
blood of patients with TMD.47,68 Additionally, elevated proinflammatory cytokine levels
have been correlated with greater pain sensitivity,31,48,65,74 perceived stress,37 and
depressed mood,38 which are phenotypes characteristic of TMD and related pain conditions.
Abnormalities in levels of proinflammatory cytokines are often accompanied by alterations
in levels of anti-inflammatory cytokines (eg, IL-1 receptor antagonist [IL-1ra]),2,32,46,68,75
associated with reductions in pain and inflammation.32,49,84
For the purpose of this study, we chose to analyze a subset of 11 cytokines from the study
data set that had reliable measures (for specific details pertaining to measurement of
cytokines, please refer to Slade et al68). This subset included the following proinflammatory
cytokines: epithelial-derived neutrophil-activating peptide 78 (ENA-78), fibroblast growth
factor basic (FGF basic), granulocyte colony stimulating factor (G-CSF), interleukin-6
(IL-6), interleukin-8 (IL-8), macrophage inflammatory protein-1β (MIP-1β), monocyte
chemotactic protein-1 (MCP-1), thrombopoietin (Tpo), tumor necrosis factor-α (TNF-α),
vascular endothelial growth factor (VEGF), and the anti-inflammatory cytokine
interleukin-1 receptor antagonist (IL-1ra). We compared levels of each cytokine between
TMD subgroups and controls using analysis of variance. For exploratory purposes, we set
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the level of significance at P < .10. Using this criterion, we identified 7 cytokines that were
associated with case status and then used to construct the index for inflammatory domain
measures (IL-6, MCP-1, MIP-1β, VEGF, Tpo, FGF, and IL-1ra).
Psychological Domain Measures—All subjects completed a battery of psychological
inventories that have been shown to be associated with TMD and other persistent pain
conditions.8,67,76,82 Multiple measures were selected to evaluate the multiple aspects of
psychological function that may contribute to “enhanced psychological distress.”20
Spielberger State-Trait Anxiety Inventory: The Spiel-berger State-Trait Anxiety
Inventory (STAI) includes two 20-item instruments measuring situational state anxiety
(STAI-1) and trait anxiety (STAI-2). It includes statements such as “I feel calm” or “I am
worried” with response options scored on a 4-point scale from 1 (not at all) to 4 (very much
so). Ten of the items are reverse scored to create an overall score of anxiety for each of the
instruments.70,71
Symptom Checklist–90 Revised: The Symptom Checklist–90 Revised (SCL-90-R)
consists of 90 items, each describing a feeling or thought, scored on a 5-point scale from 1
(not at all distressed) to 5 (extremely distressed). It provides ratings of psychological distress
in 9 symptom areas: somatization, obsessive-compulsive, interpersonal sensitivity,
depression, anxiety, hostility, phobic anxiety, paranoid ideation, and psychoticism.16 Only
the depression subscale was presented and analyzed in this study.
Pain Catastrophizing Scale: The Pain Catastrophizing Scale (PCS) consists of 14 thoughts
or feelings, including anxiety, coping, and helplessness in response to pain. Subjects rate the
degree to which they experience each item while feeling pain using a 5-point scale from 0
(not at all) to 4 (all the time).73
Pennebaker Inventory of Limbic Languidness: The Pennebaker Inventory of Limbic
Languidness (PILL) assesses the frequency of occurrence of 54 common physical symptoms
and sensations using a 5-point scale, ranging from 1 (never or almost never have) to 5 (more
than once every week). The total score of PILL represents somatic awareness. It has high
internal consistency and sufficient test-retest reliability.50
Data Reduction and Statistical Analysis
Data Reduction and Generating a Multisystem Dysregulation Index (MDI)—
Originally, 25 markers from the 4 domains were compared between TMD subgroups (with
different numbers of comorbid pain conditions) and controls using analysis of variance for
continuous variables and Pearson chi-square test for categorical variables. For exploratory
purpose, we determined the level for significance at P < .10 for selecting measures to
construct each domain index, as well as a multisystem index. This yielded a total of 20
measures from the 4 domains, which include the following: 1) sensory domain: heat pain
temporal summation, heat pain tolerance, PPT, and WPT; 2) autonomic domain: SBP, DBP,
HR, and RPP; 3) inflammatory domain: IL-6, MCP-1, MIP-1β, VEGF, Tpo, FGF basic, and
IL-1ra; and 4) psychological domain: state (STAI-1) and trait (STAI-2) anxiety, depression
(SCL-90-R–Depress), pain catastrophizing (PCS), and somatic symptom complaints (PILL).
To assess whether impairments or dysregulation in or across domains were associated with
TMD and TMD with comorbidities, we adopted Seeman’s (2001) multi-system
dysregulation risk estimation method that was developed to concurrently measure elevated
risk for dysregulation across multiple interconnected physiological systems in health
research.64 This method uses the summation of several biomarkers within “elevated-risk”
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domains to indicate the magnitude of impairment or dysregulation. In the present study,
impairment was assumed when 1) the value of an individual’s biomarker or psychological
test was at or above the 75th percentile relative to controls for heat pain temporal
summation, SBP, DBP, HR, RPP, IL-6, MCP-1, MIP-1β, VEGF, Tpo, FGF, STAI-1,
STAI-2, SCL-90-R–Depress, PCS, and PILL; or 2) the value was at or below the 25th
percentile relative to the controls for heat pain tolerance, PPT, and IL-1ra; and 3) with the
presence of WPT. A dichotomous (0 or 1, 0 = no risk and 1 = at risk) risk score was
assigned to each of the 20 measures. For each participant, the total multisystem
dysregulation index (MDItotal) was calculated as the sum of the number of markers (ie,
biomarkers and psychological tests) in the defined risk zones. The risks for domain-specific
dysregulation (ie, MDIsensory for sensory domain, MDIautonomic for autonomic domain,
MDIinflammatory for inflammatory domain, and MDIpsychological for psychological domain)
were calculated as the sum of the number of measures in the risk zone in each corresponding
domain.
Statistical Analyses—For statistical analyses, Stata for Windows (version 11; Stata
Corp, College Station, TX) was used. Descriptive statistics for demographic and clinical
characteristics, as well as for MDI total score and individual domain scores, were calculated.
Statistical significance was evaluated using analysis of variance or Student t-test for
continuous variables and Pearson chi-square test for categorical variables. The relationship
between total MDI score and occurrence of TMD and the relationship between each MDI
individual domain score and occurrence of TMD were expressed as odds ratios, calculated
from logistic regression models adjusted for covariate of age. A multinomial logistic
regression model was used to generate age-adjusted estimate of the relationship between
total MDI score and TMD subgroup status (with different numbers of comorbid pain
conditions). Additional multinomial logistic regression models were generated to estimate
the relationship between an individual MDI domain and TMD subgroup status adjusted for
other MDI domains and age. Bonferroni correction was used to determine the threshold for
statistical significance according to the number of comparisons: P < .001 for demographic
and clinical pain characteristics; P ≤.002 for multisystem dysfunction (MDI) measures and
for the rejection of null hypothesis regarding odds ratios.
Results
A total of 131 controls and 159 TMD cases were identified in this study of females aged 18
to 60 years (mean = 33.4 years, standard deviation [SD] = 12.3 years). Among TMD cases,
14 individuals reported no comorbid persistent pain condition (ie, TMD only group), 78
individuals reported 1 comorbid persistent pain condition (ie, TMD + 1 pain group), and 67
individuals reported multiple (ie, 2 or more) comorbid persistent pain conditions (ie, TMD +
≥2 pain group). Significant age differences were found between controls and TMD cases,
and among TMD subgroups with different numbers of comorbid pain conditions (Table 1,
Ps < .001).
Clinical Pain Characteristics
Morethan 90% of TMD subjects fulfilled RDC/TMD diagnosis criteria for both myalgia and
arthralgia (Table 1). On average, TMD subjects reported 9.5 ± 8.3 years of facial pain.
Facial pain intensity was at “moderate” (midscale) levels during the past 6 months (Table 1).
Overall, 50 to 60% of TMD subjects reported high intensity and/or high disability (ie, GCPS
levels II–IV) from facial pain in the past 6 months (Fig 1). TMD cases also reported an
average of 52% of waking days with “mild to moderate” levels of “head, neck, or facial
pain” in the past 1 to 2 weeks. After Bonferroni correction, no differences among TMD
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subgroups (ie, TMD only, TMD + 1 pain, TMD + ≥2 pain) were observed in any facial pain
intensity, unpleasantness, or severity measures (Table 1 and Fig 1).
In addition, 6% of controls and 65% of TMD subjects reported pain from nonfacial regions
in the past 6 months (ie, GCPS other pain, P < .001). Although none of the controls reported
high pain intensity and/or high disability from nonfacial pain, 38% of TMD cases reported
high pain intensity and/or high disability (ie, GCPS levels II–IV) from pain in nonfacial
regions. The highest proportion (59%) was observed in the subgroup of TMD with multiple
comorbid pain conditions (Ps < .001, Fig 1).
Comorbid Persistent Pain Conditions
The most prevalent comorbid persistent pain condition reported by TMD cases was frequent
headaches (ie, 84% in all TMD cases; Table 2). For the majority (91%) of cases with 1
comorbid pain, frequent headache was their only comorbid pain condition. Among those
cases with multiple comorbid pain conditions, frequent headache was reported by almost
every participant (99%). Fibromyalgia, IBS, and frequent low back pain were also highly
prevalent in the TMD subgroup with multiple comorbid pain conditions (Table 2).
Multisystem Dysregulation Measures
A total of 25 markers from 4 system domains were initially measured (ie, sensory,
autonomic, inflammatory, and psychological; see Supplementary Tables 1–4). After
exploratory analysis, 20 markers with significant difference between controls and cases were
selected to construct the multisystem dysregulation index, generating an overall risk score
for multisystem dysregulation (MDItotal) ranging from 0 to 20 (see Data Reduction section
for detailed description). Bivariate analysis showed that on average, the MDItotal score was
greater in TMD subjects than in controls (mean ± SD = 8.6 ± 3.0 vs 4.9 ± 2.5, respectively,
P ≤.001, Table 3). When further compared between each TMD subgroup and controls,
MDItotal scores were elevated in all 3 TMD subgroups after Bonferroni correction (Ps ≤ .
002; Table 3).
TMD cases as a group also showed greater MDI domain scores in all 4 system domains as
compared to controls (Ps ≤ .001; Table 3). However, individual MDI system domain scores
showed selective elevation in different TMD subgroups with different numbers of comorbid
pain conditions. Sensory domain score (MDIsensory) was greater in all TMD subgroups than
in controls, autonomic domain score (MDIautonomic) and inflammatory domain score
(MDIinflammatory) were only elevated in the subgroup of TMD + ≥2 pain conditions, and
psychological domain score (MDIpsychological) was elevated in the subgroups of TMD + 1
pain and of TMD + ≥2 pain conditions (Ps ≤ .002; Table 3).
Multivariate Analyses of the Association Between MDI Scores and TMD Case Status
Multivariate analyses showed an overall contribution of multisystem dysregulation
(MDItotal), as well as selective contributions from individual system domains to painful
TMD (Table 4). After adjustment for age, each 1 unit increase in MDItotal score (ie, 1
additional dysregulation from any assessed biomarkers or psychological tests) was
associated with 1.6 times the odds of being a TMD case (95% confidence interval [CI] =
1.4–1.8, P < .001; Table 4, Model 1). After adjustment for age and for other MDI system
domains, each 1 unit increase in MDIsensory or MDIpsychological domain scores (ie, 1
additional dysregulation from any assessed sensory or psychological measures) was
associated with approximately 2 times the odds of being a TMD case (Ps ≤ .001; Table 4,
Model 2). The contributions from autonomic domain and inflammatory domain were not
independent (Table 4, Model 2).
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To further explore the relationship between total multisystem dysregulation and the
classification of 3 TMD subgroups with different numbers of comorbid pain conditions,
multinomial logistic regression analyses were performed with adjustment for age. The
results showed that increase in MDItotal score was associated with increased odds for being a
TMD case in any subgroups compared to controls (OR [odds ratio] = 1.5, 95% CI = 1.2–2.0;
OR = 1.5, 95% CI = 1.3–1.7; and OR = 1.8, 95% CI = 1.5–2.2, for TMD only, TMD + 1
pain and TMD + ≥2 pain, respectively, Ps ≤ .002; Fig 2)
However, dysregulation in each individual system domain was associated differently with
the odds of being in a specific TMD subgroup after adjustment for age and for the
contribution from other system domains (Figs 3–6). Each 1 unit increase in MDIsensory score
(ie, 1 additional dysregulation from any assessed sensory measures) was associated with 2.8
times the odds for being a TMD case with multiple comorbid pain conditions (95% CI =
1.7–4.7, P ≤.001; Fig 3). A trend of association between increased MDIsensory score and
elevated odds for being a TMD case with no comorbid pain condition was seen (OR = 2.6,
95% CI = 1.2–5.4, P = .01; Fig 3). However, this association did not reach statistical
significance after Bonferroni correction for multiple comparisons (P ≤.002 was required for
MDI measures).
No association was seen between MDIsensory score and the odds for being a TMD case with
1 pain condition (P > .05).
With respect to the autonomic domain, a trend of association was seen between increased
MDIautonomic score and elevated odds for being a TMD case with multiple comorbid pain
conditions (Fig 4). However, this association was not significant after Bonferroni correction
(OR = 1.5, 95% CI = 1.1–2.0, P = .01). No associations were seen between MDIsensory score
and the odds for being a TMD case in the other 2 TMD subgroups.
In the inflammatory domain, no significant association between MDIinflammatory score and
the odds for being a TMD case was seen in any TMD subgroups with different comorbid
pain profiles (Fig 5).
In the psychological domain, each 1 unit increase in MDIpsychological score was associated
with 2 or more times the odds for being a TMD case with 1 or with multiple comorbid pain
conditions (OR = 2.0, 95% CI = 1.6–2.6, and OR = 2.5, 95% CI = 1.8–3.4, respectively, Ps
< .001; Fig 6). No association was seen between MDIpsychological score and the odds for
being a TMD case without comorbid pain conditions (OR = 1.6, 95% CI = 1.0–2.6, P = .05).
Discussion
Main Results
The present study explored the relationship between multiple system dysregulation in
sensory, autonomic, inflammatory, and psychological domains and painful TMD. The
results revealed that 1) dysregulation in multiple system domains, particularly in the sensory
and the psychological domains, were associated with increased likelihood of being a painful
TMD case in general and 2) dysregulations in individual system domains selectively
contribute to the increased odds of being a TMD case with different levels of comorbid
persistent pain conditions. These outcomes indicate that heterogeneous multisystem
dysregulations may exist in painful TMD subgroups with different numbers of comorbid
pain conditions, and multidimensional physiological and psychological assessments can
provide important information regarding pathophysiology, diagnosis, and management of
pain in TMD patients. These findings are consistent with the heuristic model proposed by
Diatchenko et al17 and Maixner et al.39
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Multisystem Dysregulation in Painful TMD
Extensive evidence has shown dysregulations in multiple physiological and psychological
system domains that associate with painful TMD.17,39 However, assessing the dysregulation
in 1 specific domain fails to capture the heterogeneous phenotypes and comorbid conditions
associated with painful TMD conditions. In the present study, we quantitatively measured
multiple system domains (ie, sensory, autonomic, inflammatory, and psychological) that
potentially contribute to painful TMD and its associated comorbid pain conditions. In
addition, for each assessed system domain, we selected multiple components as each of
these components may contribute to the overall dysregulation in a particular domain.20,25,40
The current selection of domain markers represents a “work-in-progress,” and additional
methodological development is required to identify the best predictive markers of
dysregulation and subgroup classification; however, the current results demonstrate several
interesting points regarding the heterogeneity of system dysregulation that manifest as a
mosaic of intermediate phenotypes (eg, signs and symptoms) associated with painful TMD.
First, when the entire sample of TMD cases is considered as 1 group, the total dysregulation
from multiple system domains (MDItotal) is elevated, which is a result of increases in the
assessed values in both the sensory and psychological domains. These results are consistent
with previous findings that enhanced pain sensitivity and psychological distress are
important risk domains for TMD (for reviews, see Diatchenko et al17 and Maixner et al39)
and further support the multidimensional biopsychosocial assessment for painful TMD.
For the domains that failed to show significant differences between cases and controls, the
interpretation should be viewed with caution. Because of secondary analysis, our selections
of autonomic domain measures were limited and may not represent the most sensitive
measures for autonomic function. Improved measures, such as using heart rate
variability,63,72 may provide better understanding of sympathetic and parasympathetic
functions in chronic pain conditions. Recent studies of autonomic function in TMD40 and
related pain conditions10,43,60 support such an approach. Furthermore, our result revealed
potential subgroup differences in autonomic function, with the most predominant autonomic
changes seen in TMD with multiple comorbid conditions. Such heterogeneity may affect the
overall group-level differences between cases and controls.
With respect to the inflammatory domain, our selected inflammatory markers did not differ
between cases and controls in the multivariate analysis after adjustment for age and other
MDI domains (Table 4, Model 2). This may indicate that the contribution from the
inflammatory domain to TMD pain is not independent, and additional analyses that explore
interactions between various risk domains are warranted. In addition, although we did not
compare between TMD subgroups because of the sample size, the inflammatory profiles
tended to be different among the TMD subgroups (Supplementary Tables 3a and 3b). For
example, TMD cases with comorbid pain conditions exhibited general trends of elevated
levels of 7 (out of 11) cytokines (IL-6, IL-8, TNF-α, MCP-1, ENA-78, FGF basic, and G-
CSF) compared to TMD without comorbid pain conditions. This finding is consistent with
the large body of literature demonstrating that elevated circulating cytokine levels are
associated with widespread pain disorders.3,28,68,69,83,90 On the other hand, the majority
(50%–60%) of TMD without comorbid pain conditions showed high VEGF and/or Tpo
levels, and 43% of this group also showed low IL-1ra levels. These patterns were not seen in
the other TMD subgroups and were novel and unexpected. On closer examination, we found
that cases with TMD alone particularly showed generalized mechanical hyperalgesia. In
animal models, mechanical hyperalgesia is associated with increased VEGF levels,36,45 and
IL-1ra blocks mechanical hyperalgesia produced by proinflammatory cytokines.15 Thus,
although a great deal of redundancy and pleiotropy exist in cytokine networks, VEGF is
likely a specific marker of mechanical hyperalgesia, and subgroup differences may affect the
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overall group-level comparison between cases and controls and require further investigation
with a larger sample. Nevertheless, our results highlight the importance in assessing
dysregulation in multiple system domains in addition to the Axis I masticatory system when
searching for pathophysiological mechanisms that promise to guide mechanism-based
interventions for painful TMD.
Second, when TMD cases were stratified by bodily pain profiles, heterogeneity in
multisystem dysregulation was seen in TMD subgroups. For those with painful TMD but
without comorbid persistent pain conditions, the predominant dysregulation was present
only in the sensory domain. This group consists of 8% of our cases with a mean age of 34
years. On average, approximately 2 (out of 4) measures in MDI sensory domain were above
the risk cutoffs including both mechanical and thermal modalities (Table 2 and
Supplementary Table 1a). Although this is a small group with only 14 cases, the inter
subject variations were fairly small for all sensory measures (Supplementary Table 1a),
indicating robust changes in this group. Our selected sensory testing sites and sensory
measures permitted the assessment of the presence of a generalized somatic sensitization
resulting from either peripheral or central nervous system mechanisms. Among the 3 TMD
subgroups, this group showed the most extensive signs of sensory sensitization; that is, in
each sensory measure, about 40 to 50% of the subjects showed elevated risk of
dysregulation (Supplementary Table 1b). Although the association between sensory
dysregulation (MDIsensory) and the odds for being a case in this group did not reach
significance in the multivariate model (P = .01; Fig 3), we suspect this was due to the small
sample size in the multivariate model (n = 9). In addition, having similar facial pain profiles
and being of similar age as TMD cases with 1 comorbid pain group indicates that this group
may have an endogenous protective mechanism(s) that protects from other comorbid pain
conditions or this group may not have experienced the same pathologic exposures that
contributes to the manifestation of associated comorbid conditions. Among the 3 TMD
subgroups, this group had a psychological profile most similar to controls. Whether
psychological resilience and a positive life history plays a protective role in this group
remains an interesting and open question.
For those with painful TMD and with 1 comorbid persistent pain condition, psychological
dysregulation was the only domain associated with increased likelihood for being a case.
This group consisted of almost half of our cases with a mean age of 33 years. In general,
subjects in this group show multiple and heterogeneous dysregulation in the psychological
domain. On average, each individual has approximately 3 (out of 5) values in the
psychological domain above the risk cutoff (Table 2 and Supplementary Table 4a). For each
psychological test, the proportion of subjects above the risk cutoffs varied from 44 to 72%
(Supplementary Table 4b). This highlights the importance of multidimensional assessment
in psychosocial distress in TMD pain20 and emphasizes the importance of improving
psychological well-being in managing painful TMD patients. In addition, we noticed that
more than 90% of this group reported “frequent headaches” as their only comorbid
persistent pain condition (Table 2). Therefore, the majority of this group still only reported
localized pain in the craniofacial region. The sensory test results for this group were similar
to those for controls, which do not show signs of enhanced pain sensitivity (Fig 3 and
Supplementary Table 1a). Because participants in the TMD + 1 pain (headache) group were
on average 7 years younger than TMD cases with multiple comorbid conditions, future
research should explore whether this younger group is predisposed to developing other
comorbid pain conditions such as chronic widespread pain, which is associated with high
levels of psychological distress.26 If so, preemptive interventions can be developed and
implemented as preventive interventions.
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For those with painful TMD and multiple comorbid persistent pain conditions, a
multisystem dysregulation was observed. Compared with controls, elevated dysregulation in
both sensory and psychological domains as well as a trend of greater dysregulation in the
autonomic domain was observed. This group consists of 42% of our cases with a mean age
of 41 years. Similar to the other TMD subgroups, this group also showed heterogeneity in
both MDIsensory (31–67% above risk cutoffs; Supplementary Table 1b) and MDIpsychological
(48–94% above risk cutoffs; Supplementary Table 4b) domains. The most predominantly
dysregulated measure was widespread palpation tenderness (67%) and somatic symptom
complaints (94%). These results are consistent with previous findings on widespread pain
conditions.51,57,88 In addition, although the difference of overall autonomic domain measure
did not reach a level of significance, more than 50% of this group had elevated resting
arterial blood pressure and 37% showed elevated resting heart rate values. Extensive
evidence has shown autonomic dysregulation in TMD and related pain conditions such as in
fibromyalgia, IBS, and CFS.7,22,40,41,43,72,79,87 In this study, the prevalence of these
comorbid pain conditions ranged from 23% (CFS) to 48% (IBS) in this TMD subgroup
(Table 2). Improved autonomic measures, such as using heart rate variablilty, may improve
the assessment for autonomic dysfunction in this TMD subgroup.
Implications and Limitations
Heterogeneity in systemic pain profiles (ie, comorbid pain) has been clearly demonstrated in
TMD populations previously.52,53 Our results are consistent with previous findings and
demonstrate heterogeneous dysregulation in multiple system domains among those with
different comorbid pain profiles in painful TMD. These results may reflect heterogeneous
pathophysiologies associated with different regulatory domains in TMD subgroups with
different numbers of comorbid pain conditions. Averaging across these subgroups may
result in inaccuracy in determining the specific pathophysiological mechanisms that
contribute to an individual TMD patient’s signs and symptoms. Therefore, recognizing
further subgroup differences is clearly possible and warrants additional methodological
development and investigation.
It is well known that multiple regulatory domains such as sensory, autonomic, immune-
inflammatory, and psychological domains can all contribute to peripheral and/or central pain
amplification. Furthermore, these regulatory domains are often interconnected and
integrated by the CNS, including CNS processes that modulate pain processing, in a manner
that maintains homeostasis under normal physiological conditions.14,44 In this context, the
impact from multiple interconnected regulatory domains may individually and/or
collectively contribute to enhanced pain states and therefore should be assessed concurrently
in examining pain perception. Currently the examination of painful TMD is focused on the
structure and function of the masticatory system (Axis I), which underestimates the
contribution from other pain-related modulatory domains and does not provide a full
understanding of the underlying mechanisms that contribute to painful TMD and related
conditions. Our results support the need to assess multiple system domains involved in pain
regulation when evaluating complex persistent pain conditions like TMD. The optimal
measures for this approach, as well as the clinical significance regarding treatment
outcomes, require further development and exploration.
There are several limitations of this study. First, the sample size, particularly in certain TMD
subgroups, is relatively small, which limited our ability to fully explore all the hypotheses.
Future study design should consider equal sample size for each TMD subgroup. Second, this
is a secondary data analysis using measures from a limited data set. Several issues are
affected by this limitation. For example, the cohort was limited to Caucasian females,
psychological or cognitive functions that might influence the subjects’ ability to rationally
interpret study questions and study demands were not assessed, and some measures (eg,
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measures in autonomic domain) were of an incomplete set. In addition, although the risk of
chronicity is of significance for understanding and managing any chronic pain conditions,
this issue could not be completely addressed because of the sample size limitation and the
lack of information on chronicity of comorbid pain conditions. Furthermore, the
dysregulation risk cutoffs were set arbitrarily, and the extent to which these cutoffs reflect
clinical significance or subclinical risk requires additional investigation. However, to our
knowledge, this is the first study that concurrently assesses pain-related multisystem
dysregulation and therefore may provide valuable information on methodology and future
models. Further prospective studies are needed to address these limitations.
Summary
Overall, the assessment of multiple physiological systems is critical to our understanding of
the pathophysiological processes that contribute to painful TMD and associated comorbid
conditions, which will ultimately guide and inform appropriate treatment strategies that
address the multisystem dysregulation associated with complex and common persistent pain
conditions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Percentage of subjects within TMD subgroups with GCPS Grades II to IV at different pain
locations. GCPS Grade I, low disability–low intensity; Grade II, low disability–high
intensity; Grade III, high disability–moderately limiting; and Grade IV, high disability–
severely limiting. GCPS Grades II to IV were selected to represent “clinical significant
pain.” *P < .001 for the following: TMD + ≥2 pain vs TMD only; TMD + ≥2 pain vs TMD
+ 1 pain.
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Likelihood of being TMD subgroup cases by total MDI score. The MDI total score is
differently associated with the odds of being TMD subgroups based on the number of
comorbid persistent pain conditions. Odds ratios were calculated for each case classification
relative to controls from a multinomial logistic regression model adjusted for age (n = 230
females). *P = .002, **P < .001.
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Likelihood of being TMD subgroup cases by sensory domain score. The MDI sensory
domain score is differently associated with the odds of being TMD subgroups based on the
number of comorbid persistent pain conditions. Odds ratios were calculated for each case
classification relative to controls from a multinomial logistic regression model adjusted for
age and dysregulation from autonomic, inflammatory, and psychological domains (n = 230
females). *P ≤.001.
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Likelihood of being TMD subgroup cases by autonomic domain score. The MDI autonomic
domain score is not associated with the odds of being TMD subgroups based on the number
of comorbid persistent pain conditions. Odds ratios were calculated for each case
classification relative to controls from a multinomial logistic regression model adjusted for
age and dysregulation from sensory, inflammatory, and psychological domains (n = 230
females).
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Likelihood of being TMD subgroup cases by inflammatory domain score. The MDI
inflammatory domain score is not associated with the odds of TMD subgroups based on the
number of comorbid persistent pain conditions. Odds ratios were calculated for each case
classification relative to controls from a multinomial logistic regression model adjusted for
age and dysregulation from sensory, autonomic, and psychological domains (n = 230
females).
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Likelihood of being TMD subgroup cases by psychological domain score. The MDI
psychological domain score is differently associated with the odds of TMD subgroups based
on the number of comorbid persistent pain conditions. Odds ratios were calculated for each
case classification relative to controls from a multinomial logistic regression model adjusted
for age and dysregulation from sensory, autonomic and inflammatory domains (n = 230
females). *P < .001.
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Table 2
Percentage of TMD Cases With Different Numbers of Comorbid Persistent Pain Condition(s)
All TMD Cases % TMD + 1 Pain % TMD + ≥2 Pain %
Fibromyalgia 18 0 43
Chronic fatigue syndrome 10 0 23
IBS 23 5 48
Interstitial cystitis 1 0 3
Chronic pelvic pain 7 0 16
Frequent headaches 86 91 99
Frequent low back pain 25 4 55
NOTE. Number of study subjects included in each group for comorbid pain conditions varies based on available information. For all TMD cases: n
= 155–159; for TMD + 1 pain, n = 75–78; for TMD + ≥2 pain, n = 65–67.
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Table 4
Multivariate Adjusted Odds Ratios Comparing MDI Scores and TMD Case (vs Noncase) Status
Model 1* Odds Ratio (95% CI) P value Model 2† Odds Ratio (95% CI) P value
MDItotal 1.6 (1.4, 1.8) .000 N/A N/A
Individual MDI domains
 MDIsensory N/A N/A 1.9 (1.3, 2.9) .001
 MDIautonomic N/A N/A 1.3 (1.0, 1.6) .046
 MDIinflammatory N/A N/A 1.1 (.9, 1.5) .368
 MDIpsychological N/A N/A 2.1 (1.7, 2.7) .000
Age 1.0 (1.0, 1.1) .07 1.0 (1.0, 1.1) .004
Abbreviation: N/A, not applicable.
NOTE. n = 230 with participants who have complete information on all tested variables in both models.
*
Model 1: estimate of MDItotal to TMD, adjusted for age.
†
Model 2: estimate of individual MDI domains to TMD, adjusted for other MDI domains and age.
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